title: Successful treatment of fibrosing cholestatic hepatitis with pegylated interferon, ribavirin and sofosbuvir after a combined kidney-liver transplantation.
abstract: Fibrosing cholestatic hepatitis (FCH) is a classical but rare and severe form of recurrent hepatitis C virus (HCV) after liver transplantation. Classical anti-HCV therapy, that is pegylated-interferon (peg-interferon) and ribavirin, has been shown to have limited efficacy in treating FCH. Herein, we report on the first case of successful use of peg-interferon, ribavirin, plus sofosbuvir to treat HCV-induced FCH in a combined liver-kidney transplant patient. Antiviral therapy was given for 24 weeks. HCV clearance occurred within 4 weeks after starting therapy and was maintained until 4 weeks after the end of therapy. Antiviral tolerance was good. We conclude that the use of sofosbuvir-based anti-HCV therapy can be successfully used to treat FCH after a liver or combined kidney-liver transplantation.
authors.affiliation: Department of Nephrology and Organ Transplantation, CHU Rangueil, Toulouse, France.
authors.forename: Cyrielle
authors.initials: C
authors.lastname: Delabaudière
authors.forename: Laurence
authors.initials: L
authors.lastname: Lavayssière
authors.forename: Gaëlle
authors.initials: G
authors.lastname: Dörr
authors.forename: Fabrice
authors.initials: F
authors.lastname: Muscari
authors.forename: Marie
authors.initials: M
authors.lastname: Danjoux
authors.forename: Federico
authors.initials: F
authors.lastname: Sallusto
authors.forename: Jean Marie
authors.initials: JM
authors.lastname: Peron
authors.forename: Christophe
authors.initials: C
authors.lastname: Bureau
authors.forename: Lionel
authors.initials: L
authors.lastname: Rostaing
authors.forename: Jacques
authors.initials: J
authors.lastname: Izopet
authors.forename: Nassim
authors.initials: N
authors.lastname: Kamar
mesh_terms: D000368:Aged; D000998:Antiviral Agents / Q000008:administration & dosage*; D004338:Drug Combinations; D006526:Hepatitis C / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage; D016030:Kidney Transplantation / Q000009:adverse effects*; D016031:Liver Transplantation / Q000009:adverse effects*; D008297:Male; D011092:Polyethylene Glycols / Q000008:administration & dosage; D011994:Recombinant Proteins / Q000008:administration & dosage; D012008:Recurrence; D012254:Ribavirin / Q000008:administration & dosage; D000069474:Sofosbuvir; D014542:Uridine Monophosphate / Q000008:administration & dosage / Q000031:analogs & derivatives
chemical_list: D000998:Antiviral Agents; D004338:Drug Combinations; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; D014542:Uridine Monophosphate; C100416:peginterferon alfa-2a; D000069474:Sofosbuvir
keywords: fibrosing cholestatic hepatitis; hepatitis C virus; kidney transplantation; liver transplantation; sofosbuvir